A host cell protein assay measures what the cells left behind: the hundreds of proteins the expression host makes that the purification train is meant to remove. The ELISA is the workhorse, and the kit is chosen by the cell line it was raised against rather than by the product, which is why a HEK 293 kit, a CHO kit and an E coli kit are not interchangeable. This page is about choosing one, and about the coverage question that decides whether the number means anything.
Why the kit is named after the cell line
The antibodies in a host cell protein kit are raised against a lysate of the production host, so what they detect is the protein population of that host grown in something like that way. A kit raised against HEK 293 lysate will under-report a CHO process and mis-report a microbial one, and even within one host the antibody pool reflects the cells and conditions the immunogen came from. That is why the first question about a result is not the number, it is which kit produced it and against what immunogen, and why changing kit mid-program forces a bridging exercise rather than a straight comparison.
Platform, generic and process-specific assays
A generic kit is sold for any process in that host and is the right starting point in development. A platform kit is raised against a lysate from a company's own standard process and is tighter. A process-specific assay is raised against the actual null cell lysate from your own process and is what a late-stage program is usually expected to move to. The progression costs money and time, and the reason to start it earlier than feels necessary is that the switch itself has to be justified with data, and doing that while the process is still changing is cheaper than doing it under a filing deadline.
Coverage is the number behind a HEK293 HCP ELISA number
An ELISA reports a total, and that total is only as good as the fraction of the host's proteins the antibody pool actually sees. Coverage is demonstrated by a separate method, classically two-dimensional electrophoresis with a Western overlay and increasingly by mass spectrometry, and it is the evidence a reviewer asks for. Ask a kit supplier what coverage has been shown, by which method and against which lysate. A kit with no coverage evidence produces a defensible-looking figure from an undefined denominator.
An E coli HCP ELISA kit, and where microbial processes differ
A microbial process changes both the impurity population and the matrix: an E coli HCP ELISA kit is raised against a very different proteome, endotoxin is a separate test rather than a footnote, and refolding steps can leave product-related species an HCP assay was never meant to see. The sample itself is also harsher on the assay, so dilutional linearity and spike recovery matter more, not less. Run both on your own in-process and final samples before trusting a single dilution.
A protein A ELISA kit measures the column, not the cells
A protein A ELISA kit is often ordered in the same breath as an HCP kit and answers a different question: how much affinity ligand has leached from the capture column into the product. It is a process impurity from the equipment rather than from the host, its acceptance limit is set differently, and the assay is sensitive to the sample treatment used to dissociate ligand from the antibody it is bound to. Treat the two as separate methods with separate validation, sharing only the sample they are run on.
Where hcp profiling goes beyond a kit
An immunoassay gives one number for everything its antiserum happens to see, which is why coverage is the question behind it. Profiling answers the other half: mass spectrometry identifies WHICH proteins are present and at roughly what level, so a process change can be judged on whether a specific difficult impurity moved rather than on whether a total drifted. The two are complementary and the assay is not replaceable, because the quantitative release test is the kit. Use profiling when a total is unexpectedly high, when a new step is introduced, or when an antiserum's coverage needs supporting evidence, and expect the answer as a list with abundances rather than as a pass.
A dsrna elisa kit, and the impurity it measures
Double stranded RNA is a byproduct of in vitro transcription and an immunostimulant, so an mRNA process measures it as a release attribute rather than a curiosity. The ELISA uses an antibody that recognizes the duplex regardless of sequence, most commonly the J2 clone, which is what makes one kit serve any transcript. Two things decide whether a number is usable: a standard that behaves like the sample, since a synthetic duplex is not the same as a process byproduct, and a dilution that puts the sample inside the range without carrying the transcript's own matrix in.
A trex1 antibody and a nuclease that prevents sensing
TREX1 degrades cytosolic DNA so that it is not sensed, and its loss causes interferon driven disease, which is why a trex1 antibody is usually used to confirm absence in a patient or engineered line rather than to measure a change. It is small and modest in abundance, so a positive control lysate and an overexpression lane make a faint band interpretable.
Questions people ask about hek 293 hcp elisa kit
Can I use a generic kit for a regulated filing?
Often in early phases, and expectations tighten as a program advances: a process-specific assay with demonstrated coverage against your own null cell lysate is what a late-stage program is usually asked for. Plan the switch and the bridging data before it is urgent.
Why do two HCP kits give different numbers on the same sample?
Because they are different antibody pools against different immunogens, so they see different fractions of the same impurity population. Neither is wrong; the numbers are not comparable, which is why a kit change needs bridging data.
Does a low HCP result mean the process is clean?
Only for the proteins the assay can see. Without coverage evidence a low total may mean good clearance or a blind antibody pool, and the two are indistinguishable from the number alone.